Trial Profile
A Phase II, Multicenter, Single-Blind, Randomized Study of the Safety and Effectiveness of SANGUINATE Versus Normal Saline in Adult Sickle Cell Disease Patients With Vaso-Occlusive Crisis (VOC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs PEG-haemoglobin carbon monoxide (Primary)
- Indications Sickle cell anaemia
- Focus Therapeutic Use
- Sponsors Prolong Pharmaceuticals
- 22 May 2018 Status changed from active, no longer recruiting to completed.
- 16 Apr 2018 Planned End Date changed from 1 Sep 2017 to 1 May 2018.
- 13 Dec 2017 According to a Prolong Pharmaceuticals media release, data from all patients are expected to be available in the first half of 2018.